Monograph Details
|
|
Dermatological Disorders
> Acne
|
|
TRI-LEGEST Fe |
| Manufacturer |
|
Barr Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Progestin + estrogen. |
| Generic Name |
|
Norethindrone acetate 1mg, ethinyl estradiol 20micrograms (5 tabs), norethindrone acetate 1mg, ethinyl estradiol 30micrograms (7 tabs), norethindrone acetate 1mg, ethinyl estradiol 35micrograms (9 tabs); inert+ (7 tabs). + contains ferrous fumarate 75mg. |
| Also |
|
• TRI-LEGEST 21
|
| Indications |
|
Moderate acne vulgaris in females ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. |
| Children |
|
Not applicable. |
| Adults |
|
Tri-Legest Fe: 1 tab daily for 28 days; repeat. Tri-Legest 21: 1 tab daily for 21 days, then 7-tablet free days; repeat. |
| Contraindications |
|
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat. X). |
| Precautions |
|
Smokers over 35 years of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended. |
| Interactions |
|
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels. |
| Adverse Reactions |
|
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders. |
| How Supplied |
|
Packs—5 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
